ERCC1 and cervical adenocarcinoma: Thus, co-administration of cisplatin and 5-FU showed synergistic or additive effects via inhibiting of ERCC1 expression, indicating a clinical advantage of combining these two drugs for suppressing ERCC1 in cervical adenocarcinoma cells.